The United Laboratories Valuation
| ULIHFDelisted Stock | USD 1.09 0.00 0.00% |
Today, the company appears to be overvalued. The United Laboratories has a current Real Value of $0.86 per share. The regular price of the company is $1.09. Our model measures the value of The United Laboratories from inspecting the company fundamentals such as Operating Margin of 0.14 %, return on equity of 0.11, and Shares Outstanding of 1.82 B as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that United Laboratories' price fluctuation is very steady at this time. Calculation of the real value of The United Laboratories is based on 3 months time horizon. Increasing United Laboratories' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the United pink sheet is determined by what a typical buyer is willing to pay for full or partial control of The United Laboratories. Since United Laboratories is currently traded on the exchange, buyers and sellers on that exchange determine the market value of United Pink Sheet. However, United Laboratories' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.09 | Real 0.86 | Hype 1.09 | Naive 1.11 |
The real value of United Pink Sheet, also known as its intrinsic value, is the underlying worth of The United Laboratories Company, which is reflected in its stock price. It is based on United Laboratories' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of United Laboratories' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of The United Laboratories helps investors to forecast how United pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of United Laboratories more accurately as focusing exclusively on United Laboratories' fundamentals will not take into account other important factors: United Laboratories Total Value Analysis
The United Laboratories is at this time forecasted to have takeover price of 850.36 M with market capitalization of 1.29 B, debt of 221.21 M, and cash on hands of 4.04 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the United Laboratories fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
850.36 M | 1.29 B | 221.21 M | 4.04 B |
United Laboratories Investor Information
About 50.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 0.67. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. The United Laboratories last dividend was issued on the 15th of September 2022. Based on the key indicators related to United Laboratories' liquidity, profitability, solvency, and operating efficiency, The United Laboratories is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March.United Laboratories Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. United Laboratories has an asset utilization ratio of 59.42 percent. This implies that the Company is making $0.59 for each dollar of assets. An increasing asset utilization means that The United Laboratories is more efficient with each dollar of assets it utilizes for everyday operations.United Laboratories Ownership Allocation
The United Laboratories shows a total of 1.82 Billion outstanding shares. The United Laboratories maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.United Laboratories Profitability Analysis
The company reported the revenue of 9.7 B. Net Income was 988.1 M with profit before overhead, payroll, taxes, and interest of 4.21 B.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates United Laboratories' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in United Laboratories and how it compares across the competition.
About United Laboratories Valuation
The pink sheet valuation mechanism determines United Laboratories' current worth on a weekly basis. Our valuation model uses a comparative analysis of United Laboratories. We calculate exposure to United Laboratories's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of United Laboratories's related companies.The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong. United Laboratories operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 13600 people.
8 Steps to conduct United Laboratories' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates United Laboratories' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct United Laboratories' valuation analysis, follow these 8 steps:- Gather financial information: Obtain United Laboratories' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine United Laboratories' revenue streams: Identify United Laboratories' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research United Laboratories' industry and market trends, including the size of the market, growth rate, and competition.
- Establish United Laboratories' growth potential: Evaluate United Laboratories' management, business model, and growth potential.
- Determine United Laboratories' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate United Laboratories' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
United Laboratories Growth Indicators
Investing in growth stocks can be very risky. If the company such as United Laboratories does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 1.8 B | |
| Quarterly Earnings Growth Y O Y | 0.02 | |
| Forward Price Earnings | 5.9067 | |
| Retained Earnings | 5.3 B |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in United Pink Sheet
If you are still planning to invest in The United Laboratories check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the United Laboratories' history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |